Ignite Creation Date:
2024-05-05 @ 10:23 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002410
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients
Sponsor:
Dupont Merck
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Phase III Multicenter Randomized Open-Label Study to Compare Antiretroviral Activity and Tolerability of Three Different Combination Regimens DMP 266 Indinavir DMP 266 Zidovudine Lamivudine Indinavir Zidovudine Lamivudine in HIV-Infected Patients
Status:
COMPLETED
Status Verified Date:
1998-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the safety and effectiveness of three anti-HIV drug combinations The three combinations are 1 efavirenz DMP 266 plus indinavir 2 DMP 266 plus zidovudine ZDV plus lamivudine 3TC and 3 indinavir plus ZDV plus 3TC This study also examines the resistance HIV may have to these drugs and if these drugs are effective over a long period of time
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| DMP 266-006 | None | None | None |